معامل آبوت

عودة للموسوعة

معامل آبوت

معامل آبوت
Abbott Laboratories
النوع عامة
رمز التداول NYSE: ABT
S&P 100 Component
S&P 500 Component
الصناعة الرعاية الصحية
تأسست 1888; 132 years ago (1888 (بإسم Abbott Alkaloidal Company)
المؤسس د. والاس كالڤن آبوت
المقر الرئيسي ليك بلف، إلينوي، الولايات المتحدة
نطاق الخدمة جميع أنحاء العالم
أشخاص رئيسيون مايلز وايت (رئيس مجلس الادارة وكبير الضباط التطبيقيين)
المنتجات Branded generic drugs
Medical devices
Diagnostic assays
منتجات تغذوية
الدخل 20.853 بليون دولار (2016)
ربح العمليات 3.185 بليون دولار (2016)
الدخل الصافي Decrease 1.4 بليون دولار (2016)
إجمالي الأصول 52.666 بليون دولار (2016)
إجمالي الأنصبة Decrease 20.538 بليون دولار (2016)
الموظفون 75,000 (2016)
Slogan LIFE. TO THE FULLEST.
المسقط الإلكتروني abbott.com

معامل آبوت Abbott Laboratories هي شركة رعاية صحية أمريكية عالمية. لديها 74،000 موظف وتعمل في أكثر من 150 بلدا. يقع مقر الشركة في ليك بلف، إلينوي. تأسست الشركة في شيكاغوعلى يد الطبيب "والاس كالڤن آبوت" في عام 1888 لهجريب الأدوية المعروفة. نمت الشركة لتبيع الأدوية القائمة على البحوث والأجهزة الطبية وفحوص التشخيص والمنتجات الغذائية. قامت بفصل قطاع المواد الصيدلانية القائمة على البحوث لشركة مستقلة باسم شركة آبڤي عام 2013. وفي عام 2015، بلغت الإيرادات 20.4 مليار دولار.

أبوت لديها مجموعة واسعة من الأدوية ذات العلامات التجارية العامة، والأجهزة الطبية، والتشخيص، ومنتجات التغذية. أعمال الشركة في التشخيص المخبري تنفذ فحوص الدم والمناعة. وتستخدم في الاختبارات الطبية وأنظمة أداة التشخيص في جميع أنحاء العالم من قبل المستشفيات والمختبرات وبنوك الدم، وممحرر الأطباء لتشخيص ومراقبة الأمراض مثل فيروس نقص المناعة البشرية والتهاب الكبد والسرطان وقصور القلب واضطرابات التمثيل الغذائي، وكذلك تقييم مؤشرات أخرى للصحة. في عام 1985، قامت الشركة بأول اختبار دم لفحص فيروس نقص المناعة البشرية.

تقوم نقاط أبوت الطبية للعناية بتصنيع منتجات تشخيصية لتحليل الدم لتوفير المعلومات للعاملين في مجال الرعاية الصحية والتشخيص في نقطة الرعاية للسقمى. كما توفر أبوت نقاط رعاية مقايسات القلب لغرف الطوارئ.

التاريخ

د. والاس آبوت

في 1888 في عمر الثلاثين، قام والاس آبوت (1857–1921)، خريج 1885 من جامعة مشيگن، بتأسيس Abbott Alkaloidal Company. في ذلك الوقت، كان يعمل طبيباً ممارساً وكان يملك صيدلية. إبداعه كان في استخدام الجزء الفعال من النباتات الطبية، التي هي عموماً شبه قلوية (مورفين، كينين، ستريكنين وكودين)، التي شكـّلها في "حبيبات ضئيلة مناسبة للجرعات". هذه المقاربة كانت ناجحة إذ أنتجت جرعات أكثر انتظاماً وفعالية للسقمى.

Abbott's first international affiliate was in London in 1907, and the company later added an affiliate in Montreal, Canada (Fact 21). Abbott started operations in Pakistan as a marketing affiliate in 1948; the company has steadily expanded to comprise a work force of over 1500 employees. Currently two manufacturing facilities located at Landhi and Korangi في كراتشي continue to produce pharmaceutical products. Expansion continued in 1962 when Abbott entered into a joint venture with Dainippon Pharmaceutical Co., Ltd., of Osaka, Japan, to manufacture radio-pharmaceuticals. In 1964, it acquired Ross Laboratories, making Ross a wholly owned subsidiary of Abbott. In 1965, Abbott's expansion in Europe continued with offices in Italy and France. Abbott Laboratories has been present in India for over 100 years through its subsidiary Abbott India Limited and it is currently India's largest healthcare products company.

According to Harvard professor Lester Grinspoon and Peter Hedblom, "في 1966 Abbott Laboratories sold the equivalent of two million doses of methamphetamine in powder form to a Long Island criminal dealer".

In 2001, the company acquired Knoll, the pharmaceutical division of BASF. In 2002, it divested the Selsun Blue brand to Chattem. Later in 2002, the company sold Clear Eyes and Murine to Prestige Brands.[] In 2004, it spun off its hospital products division into a new 14,000 employee company named Hospira, and acquired TheraSense, a diabetes-care company, which it merged with its MediSense division to become Abbott Diabetes Care. In 2006, Abbott assisted Boston Scientific in its purchase of Guidant Corporation. As part of the agreement, Abbott purchased the vascular device division of Guidant. In 2007, Ross was renamed Abbott Nutrition.

In 2007, Abbott acquired Kos Pharmaceuticals for $3.7 billion in cash.[] At the time of acquisition, Kos marketed Niaspan, which raises levels of “good,” or HDL, cholesterol and Advicor, a Niaspan combination drug for patients with multiple lipid disorders.

In January 2007, the company agreed to sell its in vitro diagnostics and Point-of-Care diagnostics divisions to General Electric for more than $8 billion. These units were slated to be integrated into the GE Healthcare business unit. The transaction was approved by the boards of directors of Abbott and GE and was targeted to close in the first half of 2007. However, on July 11, 2007, Abbott announced that it had terminated its agreement with GE because the parties could not agree on the terms of the deal.

On September 8, 2007, the company completed the sale of the UK manufacturing plant at Queenborough to Aesica Pharmaceuticals, a private equity-owned UK manufacturer. No announcements have been made restricting the movement of staff to Abbott unlike other sell outs. On February 26, 2009, the company completed its acquisition of Advanced Medical Optics based in Santa Ana, California. In 2009, Abbott opened a satellite research and development facility في منتزه الأبحاث، جامعة إلينوي في إربانا-شامپين.[]

In February 2010, Abbott completed its $6.2 billion (EUR 4.5 billion) acquisition of the pharmaceuticals unit of Solvay S.A.. This provided Abbott with a large and complementary portfolio of pharmaceutical products and also expanding its presence in key emerging markets.

في 22 مارس 2010, the company completed its acquisition of a هولي‌وود، فلوريدا-based LIMS company STARLIMS. Under the terms of the deal, Abbott Laboratories acquired the company for $14 per share in an all-cash transaction valued at $123 million. On May 21, 2010, Abbott Laboratories said it would buy Piramal Healthcare Ltd.'s Healthcare Solutions unit for $2.2 billion to become the biggest drug company in India.

In October 2011, the company announced that it planned to separate into two companies, one research-based pharmaceuticals and the other in medical devices, generic drugs sold internationally, and consumer products, with device company retaining the Abbott name. The company announced that the other company would be named AbbVie in March 2012. In preparation for the reorganization, Abbott made severe budget cuts and took a $478 million charge in Q3-2012 to pay for the restructuring. The separation was effective as of January 1, 2013. AbbVie was officially listed in the New York Stock Exchange on January 2, 2013.

On May 16, 2014, it was announced that Abbott would acquire the holding company Kalo Pharma Internacional S.L. for $2.9 billion in order to secure the 73% it held of Chilean pharmaceutical company, CFR Pharmaceuticals, which the company said would more than double its branded generic drug portfolio..

In June 2014 the company entered into a definitive agreement to take over Russian pharmaceutical manufacturer Veropharm (Voronezh) in a deal worth $631 million. Abbott, which already employs 1,400 people in Russia, said it planned to set up a manufacturing presence in the country when the deal closed.

In February 2016, the company announced it would acquire Alere for $5.8 billion. In late April, of the same year, Abbott announced it would acquire St. Jude Medical for $25 billion (each share receiving $46.75 in cash & 0.8708 shares of Abbott common stock, equating to an approximate value of $85).


انظر أيضاً

  • List of biotechnology companies
  • List of Illinois companies
  • List of pharmaceutical companies

مراجع

  1. ^ "2015 Abbott Annual Report 10k".
  2. ^ "Contacts - Abbott U.S."
  3. ^ "2015 Abbott Annual Report 10k".
  4. ^ "Abbott Laboratories Archived 14 July 2014 at the Wayback Machine.", Abbott Laboratories. Retrieved July 07, 2014.
  5. ^ "Abbott Laboratories Company History". Funding Universe. Retrieved April 17, 2013.
  6. ^ "About Us".
  7. ^ "It's essential to be part of the extraordinary future India is building: Miles D. White". intoday.in.
  8. ^ Grinspoon, Lester; Hedblom, Peter (1975). . Cambridge, Massachusetts: Harvard University Press. p. 23. ISBN . OCLC 1362148.
  9. ^ Layne, Rachel; Lopatto, Elizabeth (July 11, 2007). "GE, Abbott End $8.13 Billion Diagnostic Sale Deal (Update2)". Bloomberg News.
  10. ^ Abbott Press Release (February 16, 2010). "Abbott Completes Acquisition of Solvay Pharmaceuticals". Retrieved March 22, 2012.
  11. ^ "Abbott Laboratories Feb 2010 Current Report, Form 8-K, Filing Date Feb 16, 2010" (PDF). secdatabase.com. Retrieved Dec 27, 2012.
  12. ^ Abbott Press Release (March 22, 2010). "Abbott Completes Acquisition of STARLIMS Technologies". Retrieved March 22, 2012.
  13. ^ Abbott 2011 annual report, p43
  14. ^ Abbott Press Release (May 21, 2010). "Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramal's Healthcare Solutions Business". Retrieved March 22, 2012.
  15. ^ "Abbott Labs to Split Into 2 Companies". New York Times Dealbook. October 19, 2011.
  16. ^ Rockoff, Jonathan D. (20 October 2011). "Abbott to Split Into Two Companies". Wall Street Journal.
  17. ^ Schorsch, Kristen (March 21, 2012). "Abbott picks name for spinoff pharmaceutical company". Crain's Chicago Business.
  18. ^ Frost, Peter (October 17, 2012), "Abbott lays off 550", Chicago Tribune, http://www.chicagotribune.com/business/breaking/chi-abbott-lays-off-550-20121017,0,4039023.story, retrieved on November 16, 2012 
  19. ^ Armstrong, Drew (2 January 2013). "AbbVie Rises on First Day of Trading After Abbott Spinoff". Bloomberg News.
  20. ^ خطأ استشهاد: وسم <ref> غير سليم؛ لا نص تم توفيره للمراجع المسماة :0
  21. ^ Bloomberg Release (May 16, 2014). "Abbott to acquire CFR Pharmaceuticals". Retrieved May 16, 2014.
  22. ^ Staff (15 June 2014). "Abbott Grows Branded Generics with $3.3B CFR Acquisition". News | Industry Watch. Genetic Engineering & Biotechnology News (Paper). 34 (12). p. 8.
  23. ^ "Abbott Laboratories (ABT) Key Developments - Reuters.com". reuters.com.
  24. ^ "Abbott to Acquire Alere for $5.8B". GEN.
  25. ^ Michelle Cortez (1 February 2016). "Abbott's $5.8 Billion Deal for Alere Is Device Sector's Latest". Bloomberg.com.
  26. ^ Michelle Cortez (28 April 2016). "Abbott to Buy St. Jude Medical in Deal Valued at About $25 Billion". Bloomberg.com.
  27. ^ "Abbott-St. Jude Combination: Why It Makes Sense". Bloomberg.com. 28 April 2016.

روابط خارجية

  • abbott.com Official website
Business data
  • Abbott at Google Finance
  • Abbott at Google Finance
  • Abbott at Yahoo Finance
  • Abbott at Yahoo Finance
  • Abbott at Reuters
  • Abbott SEC filings at EDGAR Online
  • Abbott SEC filings at the Securities and Exchange Commission
تاريخ النشر: 2020-06-07 13:03:23
التصنيفات: صفحات بأخطاء في المراجع, Webarchive template wayback links, CS1 errors: deprecated parameters, Pages using deprecated image syntax, شركات مدرجة في بورصة نيويورك, All articles with unsourced statements, Articles with unsourced statements from November 2015, Articles with invalid date parameter in template, Articles with unsourced statements from July 2016, معامل آبوت, تأسيسات 1888 في الولايات المتحدة, شركات مقرها في مقاطعة ليك، إلينوي, شركات أمريكية تأسست في 1888, Multinational health care companies, ليك بلف، إلينوي, شركات أدوية في الولايات المتحدة, شركات طب بيطري, شركات الرعاية الصحية في الولايات المتحدة, شركات تقانة حيوية في الولايات المتحدة, شركات صناعة أدوية في الولايات المتحدة, شركات متعددة الجنسيات مقرها في الولايات المتحدة, صناعة علوم الحياة, صفحات تستعمل قالبا ببيانات مكررة

مقالات أخرى من الموسوعة

سحابة الكلمات المفتاحية، مما يبحث عنه الزوار في كشاف:

ما هو كشاف؟